Pharmacological effects of oral L-citrulline and tetrahydrobiopterin in patients with peripheral artery disease

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/545964

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Citrulline, named after citrullus vulgaris, the watermelon, is a precursor of arginine. Arginine is converted to protective nitric oxide (NO), which is decreased in cardiovascular diseases (CVD). Although arginine supplementation can increase NO availability and improve vascular function it is hampered by a low availability. In contrast, Citrulline is highly available and converted to Arginine. Therefore, this project will explore the therapeutic effects of Citrulline in patients with CVD.

Funded Activity Details

Start Date: 01-01-2009

End Date: 01-01-2010

Funding Scheme: NHMRC Project Grants

Funding Amount: $322,283.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Medical biochemistry - inorganic elements and compounds

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Arterial function | Atherosclerotic cardiovascular disease | Dietary supplementation | L-citrulline | Peripheral arterial disease | atherosclerosis | endothelial function | tetrahydrobiopterin | vascular nitric oxide synthesis

Related Links